Danish drug maker Novo Nordisk A/S says its first quarter profit soared 15 percent on the back of increased sales of its core insulin products.
The world's top producer of insulin said net profit in the January to March period reached 4.6 billion kroner ($818 million), up from 4.1 billion kroner in the same period in 2010.
Sales increased by 13 percent to 17.8 billion kroner ($3.16 billion) from 15.69 billion kroner.
Novo Nordisk said its forecast for operating profit growth in 2012 "to be at least 10 percent" while sales growth in 2012 would be in the range of 8 and 11 percent
The company's shares rose 2.5 percent to 838.50 kroner in morning trading in Copenhagen.
Novo Nordisk employs 32,000 people in 75 countries.